Olanzapine use in women with antipsychotic-induced hyperprolactinemia.
Canuso
C M
CM
Hanau
M
M
Jhamb
K K
KK
Green
A I
AI
D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced / Q000188:drug therapy; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001569:Benzodiazepines; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000188:drug therapy*; D008875:Middle Aged; D000077152:Olanzapine; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D010546:Perphenazine; D018967:Risperidone; D000077152:Olanzapine